TH17 Cells May Serve as Biomarker in Metastatic Melanoma
Source: Targeted Oncology, September 2024
TH17 cells may be a potential biomarker to predict the risk of immune-related adverse events in patients with metastatic melanoma receiving the combination therapy of nivolumab, ipilimumab, and tocilizumab.
T Helper 17 (TH 17) cells may be a potential biomarker to predict the risk of immune-related adverse events (irAEs) in patients with metastatic melanoma receiving the combination therapy of nivolumab (Opdivo), ipilimumab (Yervoy), and tocilizumab (Actemra). Regulatory T (Treg) cells, GP130, IL-6, and osteopontin may also serve as markers to monitor treatment response and efficacy, according to data from the phase 2 S19-00008 study (NCT03999749). Data were presented by Teruyuki Mizutani, MD, PhD, at the 2024 American Society of Clinical Oncology Breakthrough meeting held from August 8 to 10, 2024, in Yokohama, Japan.
“High levels of IL-6 are found in the serum of patients with metastatic melanoma and other cancers. Circulating IL-6 levels are associated with poor outcome in immune checkpoint inhibitors. Our aim was to investigate the effect of tocilizumab, an IL-6 receptor antagonist, on immune checkpoint inhibitors,” Mizutani, of New York University Langone Medical Center in New York, said during the presentation of the data.